This week I was delighted to attend the World Drug Safety Congress Americas 2018 which took place in Philadelphia. The Congress focuses on pharmacovigilance in the pharmaceutical industry and covers a wide range of topics relating to drug safety including; integration, data source, signal detection, safety analytics and regulation.
Of the many fascinating presentations and discussions I attended, the stand out issue for me was how the capture of purer, standardised adverse event data at source, combined with new SaaS technologies and analytics, is revolutionising drug development.
The ability to capture data at source not only removes the requirement for laborious and inefficient manual data input, but also feeds AI platforms and enhances post-capture evaluation of product safety and efficacy across drug development and post-marketing. Such interpretation and quantification of product benefit-risk and more individual level is driving the development of more refined and effective drugs.
Advanced SaaS platforms, like Reportum, provide multi-lingual, multi-platform solutions that are able to integrate with other complementary technologies and associated statistical tools to facilitate the earliest detection of safety or product quality issues. This ability, combined with the rise of real-world data and companion diagnostics is revolutionising drug development and post-marketing activities, helping to provide patients with commercially viable, effective medicines.